coverage-rights
Insurer denial rates, appeal outcomes by treatment and condition, and appeal rights lookups.
我该使用它吗
质量与安全性
发现(1)
- LOW在 rank_denial_rates 中
基于对工具定义和协议合规性的自动分析。
上下文开销
这是每次将服务器的工具加载到模型上下文窗口时所消耗的大致 token 数。数值越高,可用于其他任务的注意力就越少。
安装
一键安装
将以下内容添加到你的 `claude_desktop_config.json` 文件中:
{
"mcpServers": {
"coverage-rights": {
"url": "https://coverage-rights.com/api/mcp"
}
}
}远程端点
https://coverage-rights.com/api/mcpstreamable-httphttps://www.coverage-rights.com/api/mcpstreamable-http它能做什么
工具清单
工具(9)
🟢list_insurers
List tracked U.S. health insurers with whether verified CMS-0057-F prior-authorization metrics are available for each.
输入模式
{
"type": "object",
"properties": {},
"$schema": "http://json-schema.org/draft-07/schema#"
}🟢get_insurer_metrics(slug)
Get an insurer's verified CY2025 prior-authorization metrics (denial rate, appeal overturn rate, decision times) from its own CMS-0057-F disclosure, plus contract/plan-level rows where collected. Includes source URLs and scope notes.
输入模式
{
"type": "object",
"properties": {
"slug": {
"type": "string",
"description": "Insurer slug from list_insurers, e.g. 'unitedhealthcare'"
}
},
"required": [
"slug"
],
"additionalProperties": false,
"$schema": "http://json-schema.org/draft-07/schema#"
}🟢rank_denial_rates
Insurer prior-authorization denial rates (CY2025), ranked only within compatible reporting cohorts. Each row includes its cohort, rank within that cohort, exact source scope, calculation method, and source link. Never compare ranks across cohorts.
输入模式
{
"type": "object",
"properties": {},
"$schema": "http://json-schema.org/draft-07/schema#"
}🟢get_treatment_outcomes(slug)
External-review outcomes for a treatment: how often insurer denials of this treatment/drug/procedure were overturned by independent reviewers (42,749 published CA IMR decisions, 2001–2026). Accepts a category slug (e.g. 'pharmacy') or specific treatment slug (e.g. 'zepbound', 'speech-therapy').
输入模式
{
"type": "object",
"properties": {
"slug": {
"type": "string",
"description": "Treatment slug, e.g. 'zepbound', 'pharmacy', 'speech-therapy'. Use search_outcomes to find slugs."
}
},
"required": [
"slug"
],
"additionalProperties": false,
"$schema": "http://json-schema.org/draft-07/schema#"
}🟢get_condition_outcomes(slug)
External-review outcomes for a medical condition: how often insurance denials involving this condition were overturned, plus the most-fought treatments for it.
输入模式
{
"type": "object",
"properties": {
"slug": {
"type": "string",
"description": "Condition slug, e.g. 'obesity', 'autism', 'hepatitis-c'"
}
},
"required": [
"slug"
],
"additionalProperties": false,
"$schema": "http://json-schema.org/draft-07/schema#"
}🟢search_outcomes(query, limit)
Search treatments (categories + specific drugs/procedures) and conditions by name. Returns slugs for get_treatment_outcomes / get_condition_outcomes plus headline overturn rates.
输入模式
{
"type": "object",
"properties": {
"query": {
"type": "string",
"minLength": 2,
"description": "Search text, e.g. 'wegovy', 'back pain', 'imaging'"
},
"limit": {
"type": "integer",
"minimum": 1,
"maximum": 50,
"description": "Max results per type (default 10)"
}
},
"required": [
"query"
],
"additionalProperties": false,
"$schema": "http://json-schema.org/draft-07/schema#"
}🟢get_appeal_rights(program, denial_reason, state, insurer_slug, employer_type, ...)
Deterministically resolve the governing appeal route, missing facts, filing recipient, deadlines, current external-review status, and verified grounds. Distinguishes Original Medicare, Medicare Advantage medical benefits, Part D pharmacy benefits, employer funding/governance, ACA, Medicaid, FEHB, TRICARE, and unknown coverage; unsupported or ambiguous routes fail closed.
输入模式
{
"type": "object",
"properties": {
"program": {
"type": "string",
"enum": [
"medicare-advantage",
"original-medicare",
"medicare-part-d",
"erisa-employer-plans",
"aca-marketplace",
"medicaid",
"fehb",
"tricare",
"other-unknown"
],
"description": "Plan type"
},
"denial_reason": {
"type": "string",
"enum": [
"medical-necessity",
"experimental-investigational",
"prior-authorization",
"out-of-network",
"not-covered-benefit",
"coding-billing-error",
"prescription-drug"
],
"description": "Denial reason category. Use 'prescription-drug' for medication denials — formulary exclusion, step therapy, quantity limits, or drug prior authorization — which return the formulary-exception grounds and their short decision deadlines."
},
"state": {
"type": "string",
"minLength": 2,
"maxLength": 2,
"description": "Two-letter state code, e.g. 'ca'"
},
"insurer_slug": {
"type": "string",
"description": "Insurer slug for insurer-specific stats"
},
"employer_type": {
"type": "string",
"enum": [
"private",
"government",
"church",
"union",
"unknown"
],
"description": "Required to resolve job-based coverage"
},
"funding_status": {
"type": "string",
"enum": [
"fully-insured",
"self-funded",
"unknown"
],
"description": "Required to resolve job-based state versus federal governance"
},
"drug_channel": {
"type": "string",
"enum": [
"not-a-drug",
"medical-benefit",
"pharmacy-benefit",
"unknown"
],
"description": "For a drug denial, whether the medical or pharmacy benefit applies"
},
"regulatory_marker": {
"type": "string",
"enum": [
"state-regulated",
"federal-or-self-funded",
"unknown"
]
},
"regulatory_state_basis": {
"type": "string",
"enum": [
"denial-letter",
"insurance-card",
"plan-document",
"residence-only",
"unknown"
]
},
"appeal_stage": {
"type": "string",
"enum": [
"initial-denial",
"internal-appeal-filed",
"first-internal-denial",
"final-internal-denial",
"external-review-filed",
"unknown"
]
},
"current_status": {
"type": "string",
"enum": [
"awaiting-service",
"receiving-service",
"service-ended",
"post-service-claim",
"unknown"
]
}
},
"required": [
"program",
"denial_reason"
],
"additionalProperties": false,
"$schema": "http://json-schema.org/draft-07/schema#"
}🟢get_drug_playbook(drug)
Drug-specific denial patterns and appeal strategy for the medications plans fight hardest over: GLP-1s (Wegovy, Zepbound, Mounjaro, Ozempic, Saxenda) and IBD biologics (Humira, Skyrizi, Stelara, Entyvio, Remicade, Rinvoq). Returns FDA-approved indications stated conservatively, why plans deny that specific drug, what winning appeals argue, and the step-therapy exception framing — plus the published external-review record for the drug when the corpus has it. Accepts a brand or generic name.
输入模式
{
"type": "object",
"properties": {
"drug": {
"type": "string",
"minLength": 2,
"maxLength": 80,
"description": "Brand or generic drug name, e.g. 'Zepbound', 'ustekinumab'"
}
},
"required": [
"drug"
],
"additionalProperties": false,
"$schema": "http://json-schema.org/draft-07/schema#"
}🟢get_state_external_review(state)
How a state's external review process works: filing deadline, regulator contact, and key facts. Verified detail currently covers 10 states (CA, TX, FL, NY, PA, IL, OH, GA, NC, MI); other states return the covered list.
输入模式
{
"type": "object",
"properties": {
"state": {
"type": "string",
"minLength": 2,
"maxLength": 2,
"description": "Two-letter state code, e.g. 'ca', 'ny', 'fl'"
}
},
"required": [
"state"
],
"additionalProperties": false,
"$schema": "http://json-schema.org/draft-07/schema#"
}社区
证据